A 2024 mouse study measured 3.5% oral bioavailability
its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration
Read our full take on what's at stake for patients and providers below
Safety, tolerability, and best practices Animal studies show BPC 157 peptide to have a favorable safety signal
- Whole-body imaging of even low-activity levels of Lu-177 using a new "Low Activity mode." - Immediate post-administration visualization of organ-specific uptake, such as in the salivary glands (which is relevant since salivary glands can be affected in these therapies)
